依达拉奉联合双抗治疗进展性缺血性卒中炎性因子及生活能力影响.docVIP

依达拉奉联合双抗治疗进展性缺血性卒中炎性因子及生活能力的影响 　　【摘要】 目的：观察依达拉奉联合双抗治疗进展性缺血性卒中患者血清炎性因子和生活能力的改善效果。方法：选取2015年1月-2016年12月在本院诊治的进展性卒中患者60例作为研究对象，根据抗凝方案将其分为双抗组29例接受常规双抗抗凝治疗（拜阿司匹林联合氯吡格雷），联合组31例使用依达拉奉联合双抗治疗，分别检测比较治疗前后血清炎性因子和评价生活能力。结果：治疗后，联合组血清IL-6（216.94±24.87）pg/mL、TNF-α（1.01±0.24）pg/mL、hs-CRP（3.29±0.97）mg/mL、CSS评分（10.67±1.96）分均显著低于双抗组，Barthel评分（84.26±10.98）分显著高于双抗组，两组比较差异均有统计学意义（P0.05）。结论：依达拉奉联合双抗抗凝方案能够抑制进展性卒中患者血清炎性因子表达，提升患者的生活能力，对进展性卒中预后有明显改善效果。 　　【关键词】 进展性卒中； 依达拉奉； 拜阿司匹林； 氯吡格雷； 炎性因子； 生活能力 　　【Abstract】 Objective：To observe the effect of edaravone combined with double antibody in the treatment of inflammatory factors of progressive ischemic stroke and living ability.Method：60 cases of progressive stroke treated in our hospital from January 2015 to December 2016 were selected as the research objects.According to the anticoagulant regimen，they were divided into double resistance group of 29 cases and combined group of 31 cases.The double resistance group was treated with Aspirin and Clopidogrel，the combined group was treated with both anti dual therapy and Edaravone.Before and after treatment，the serum inflammatory factors were measured，andliving ability were evaluated.Result：After treatment，the levels of serum IL-6（216.94±24.87）pg/mL，TNF-α（1.01±0.24）pg/mL，hs-CRP（3.29±0.97）mg/mL，and CSS score（10.67±1.96）scores were significantly lower than those of the double antibody group，barthel score index was （84.26±10.98）point significantly higher than that of double antibody group，the differences were statistical significance（P0.05）.Conclusion：Edaravone combined with double anti-coagulation regimen can inhibit the expression of serum inflammatory cytokines in patients with progressive stroke and improve the living ability of patients，it has obvious effect on the prognosis of progressive stroke. 　　【Key words】 Progressive stroke； Edaravone； Bayaspirin； Clopidogrel； Inflammatory factor； Living ability 　　First-author’s address：The People’s Hospital of Jiangmen City，Jiangmen 529000，China 　　doi：10.